Absorption and Digestion Kinetics of Human Metabolites

Postprandial Inflammation Clinical Trial

Official title: Absorption and Digestion Kinetics of Human Metabolites

Status Completed

Clinical Trial Summary

The purpose of this pilot study is to evaluate the effects oral supplementation with four human metabolites (spermidine, nicotinamide, palmitoylethanolamide (PEA), and oleoylethanolamide(OEA)) at varying doses on the circulating blood levels of these metabolites as well as their immediate effects on plasma functionality and postprandial inflammation. 5 young healthy subjects will participate in a four armed study consisting of a Placebo arm and a Low, Medium, and High Dose arm. Subjects will be given a standardized breakfast along with supplementation with either an escalating dose (Low: 1x, Medium: 2x, High: 3x) of a combination of spermidine, nicotinamide, PEA and OEA or a placebo control and a time course of their blood plasma will be collected after supplementation. Plasma samples will be assessed for their concentration of spermidine, nicotinamide, PEA, and OEA as well as their experimental and clinical functionalities including their anti-inflammatory, antioxidant, and cholesterol efflux abilities on primary human macrophage.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Inflammation
• Postprandial Inflammation

• NCT number: NCT05017428
• Study type: Interventional
• Source: University of California, Davis
• Status: Completed
• Phase: N/A
• Start date: April 8, 2021
• Completion date: July 1, 2021